See every side of every news story
Published loading...Updated

Knocking Down Barriers to Precision Oncology with Companion Diagnostics

Summary by Inside Precision Medicine
More than 25 years ago, the FDA approved the first companion diagnostic assay. Still in use today, the HercepTestTM marked a before and after in precision oncology, allowing the approximately 20% of women with HER2 positive breast cancer to receive targeted therapies. Since then, research and development in companion diagnostics has grown exponentially. “Today there are more than 60 companion diagnostics approved by the FDA, most of these in the…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Inside Precision Medicine broke the news in on Wednesday, April 2, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.